Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects
Status:
Completed
Trial end date:
2012-05-08
Target enrollment:
Participant gender:
Summary
The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG
145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein
cholesterol (LDL-C) in patients with hypercholesterolemia unable to tolerate an effective
dose of a statin.